Product image of Mykofenolatmofetil Actavis (Mycophenolate Mofetil) supplied by GNH India

Mykofenolatmofetil Actavis

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Mykofenolatmofetil Actavis (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mykofenolatmofetil Actavis, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ‑transplant rejection and to treat selected autoimmune disorders such as lupus nephritis and vasculitis.

GNH India supplies Mykofenolatmofetil Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Manufacturer / TM Owner

Actavis Group Ptc Ehf.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mykofenolatmofetil Actavis is used in immunosuppressive regimens for organ transplantation and autoimmune disease management.

  • Prevention of graft rejection: reduces the risk of acute and chronic rejection after solid‑organ transplantation.
  • Lupus nephritis: helps control renal inflammation and proteinuria in systemic lupus erythematosus.
  • ANCA‑associated vasculitis: contributes to disease remission and preservation of organ function.

How It Works

  • Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blockade limits guanosine nucleotide synthesis, a pathway essential for the proliferation of T and B lymphocytes, thereby suppressing the immune response without markedly affecting other cell types.

Side Effects

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: frequent loose stools, may lead to dehydration.
  • Headache: transient cranial discomfort.
  • Abdominal pain: cramping or discomfort in the stomach area.
  • Upper respiratory infections: increased susceptibility to colds.

Serious or Rare Side Effects

  • Leukopenia: significant reduction in white blood cells.
  • Anemia: decreased red blood cell count causing fatigue.
  • Severe infections: opportunistic bacterial, viral or fungal infections.
  • Hepatotoxicity: elevated liver enzymes or liver injury.
  • Malignancy risk: potential increased incidence of certain cancers.
  • Progressive multifocal leukoencephalopathy: rare but serious brain infection.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety measures.

  • Monitor blood counts: perform regular CBC to detect leukopenia or anemia.
  • Assess renal function: adjust dosing in patients with impaired kidney function.
  • Avoid live vaccines: increased risk of vaccine‑derived infection.
  • Pregnancy considerations: discuss potential fetal risks with the prescribing physician.
  • Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Mykofenolatmofetil Actavis may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Azathioprine: additive bone‑marrow suppression can cause severe cytopenias.
  • Strong CYP3A4 inhibitors (e.g., ritonavir): increase mycophenolic acid exposure and toxicity.
  • Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Warfarin: may alter INR, requiring more frequent monitoring.
  • Inactivated vaccines: possible reduced immunogenicity, monitor protective titers.
  • Antacids or sucralfate: may affect absorption of mycophenolic acid, separate administration times.

Frequently Asked Questions

Mykofenolatmofetil Actavis, containing mycophenolate mofetil, is prescribed to prevent rejection after solid‑organ transplantation and to treat certain autoimmune diseases such as lupus nephritis and ANCA‑associated vasculitis. It works by suppressing the immune system to reduce tissue damage.

Mycophenolate mofetil is converted to mycophenolic acid, which selectively blocks the enzyme inosine monophosphate dehydrogenase (IMPDH). This inhibition reduces guanosine nucleotide synthesis, a critical step for the proliferation of T and B lymphocytes, thereby dampening the immune response.

The dosage of Mykofenolatmofetil Actavis is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and concomitant therapies. Patients should follow the exact regimen provided by their healthcare professional.

Safety in pregnancy and lactation has not been fully established. The drug may pose risks to the fetus and should only be used if the potential benefits outweigh the risks, as determined by a qualified physician. Breastfeeding mothers should discuss potential exposure with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mykofenolatmofetil (mycophenolate mofetil) offers selective inhibition of lymphocyte proliferation, which can result in a different side‑effect profile compared with calcineurin inhibitors like cyclosporine or tacrolimus. It is often used in combination regimens to balance efficacy and toxicity, but the choice depends on the transplant protocol and patient tolerance.

Store the product at ambient temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight, and excessive heat to maintain stability and potency.

Mykofenolatmofetil Actavis is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. The exact dosing schedule should be followed precisely, and doses should not be altered without medical advice.

Serious risks include severe infections, leukopenia or anemia, liver toxicity, and a potential increased risk of certain malignancies. Patients should be monitored regularly for blood‑cell counts, liver function, and signs of infection, and should report any unusual symptoms promptly.

Patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation should avoid the drug. It is also contraindicated in individuals with uncontrolled severe infections or active malignancy, and caution is advised in pregnant or breastfeeding women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT